The Joint Corp. reported a strong first quarter for 2026, showcasing a significant transition to a nearly pure franchisor model. Revenue from continuing operations rose 13% year-over-year to $14.8 million, while adjusted EBITDA surged to $2.2 million from just $46,000 in Q1 2025. Notably, net income turned positive at $1.1 million, a turnaround from a loss of $506,000 in the prior year, highlighting improved profitability amid ongoing refranchising efforts.
This shift to a franchisor model is expected to enhance margins and free cash flow, with management anticipating a gross margin of 83%-85% and an adjusted EBITDA margin of 19%-21% post-refranchising. Despite a 4.2% decline in same-store sales, early signs of recovery are evident, with a sequential improvement to negative 3% in April. The company is also implementing strategic pricing initiatives and expanding B2B partnerships to bolster patient engagement and revenue.
Investors should note the potential for sustained profitability and growth as The Joint completes its refranchising strategy, positioning itself for a robust performance in the latter half of 2026 and beyond.
Source: fool.com